Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) | RFA DA 22 010

FAQs: NIH Grant Opportunity RFA-DA-22-010 (R01) - Delivery Technologies for HIV and Substance Use Disorders (SUD)

What is this funding opportunity (RFA-DA-22-010) trying to support?

This NIH funding opportunity supports R01 research projects focused on creating or significantly improving technologies that can deliver research or therapeutic payloads in the context of HIV and/or substance use disorders (SUD). The central theme is delivery: projects should treat delivery limitations as the core technical barrier and propose platform technologies, methods, or enabling tools that improve the ability to get a given "cargo" to the right cells or tissues.

What is the main problem this grant is trying to solve?

Many promising pharmacological agents, gene editing tools, and other biological or chemical payloads cannot reliably reach their intended targets. This can prevent researchers from answering key mechanistic questions and can slow or block progress toward therapeutic approaches. This opportunity is aimed at overcoming those delivery challenges (efficiency, safety, consistency, targeting, and related constraints).

What types of projects are a good fit for this RFA?

Projects are a good fit when the proposal is fundamentally about advancing delivery technology, rather than primarily testing a drug or therapeutic concept. Competitive projects typically explain what delivery limitation is blocking progress, what new or improved delivery approach will overcome that limitation, and how that improved delivery will enable HIV and/or SUD-focused mechanistic research or therapeutic exploration.

Does the project have to be about HIV, SUD, or both?

The delivery technology development must be tied to HIV and/or substance use disorders research. The opportunity is framed around delivery barriers that affect HIV and SUD research questions and payloads.

What does "cargo" mean in this opportunity?

"Cargo" refers to the payload being delivered to cells or tissues. The scope is broad. The description explicitly includes pharmacological agents and gene editing systems, and it leaves room for other payload types that are important for mechanistic studies or translational work in HIV and SUD.

What are examples of cargo types that could fall within scope?

Based on the description, cargo could include small molecules, biologics, nucleic acids, gene editing components, and other experimental payloads where delivery challenges limit effectiveness, specificity, durability, or interpretability in research models.

What kinds of delivery improvements are emphasized?

The opportunity emphasizes innovations that improve targeting, uptake, distribution, stability, controlled release, or overall feasibility of delivering the cargo to its intended target. The focus is on enabling better research outcomes and/or clearer paths toward therapeutic exploration in HIV and/or SUD.

Is this grant more about technology development or basic biology?

The primary spotlight is on technology development for delivery. While the end use can include mechanistic insight or therapeutic exploration, the proposal is expected to make delivery the central technical barrier being solved and to show how the technology improves what researchers can do in HIV and/or SUD contexts.

What is the activity mechanism for this opportunity?

The activity mechanism is an R01 (Research Project Grant).

Are clinical trials allowed under this funding opportunity?

Clinical trials are listed as optional. That means projects may be purely preclinical/mechanistic, but clinical translation is not automatically excluded if a well-justified clinical study is proposed. The description still places the primary emphasis on delivery technology development.

Who is eligible to apply?

Eligibility is broad. Eligible applicants include various levels of government (state, county, city/township, special districts), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education), for-profit organizations (other than small businesses), and small businesses.

Are tribal entities eligible?

Yes. Eligible applicants include federally recognized Native American tribal governments, public housing authorities/Indian housing authorities, and Native American tribal organizations other than federally recognized tribal governments. The opportunity also explicitly mentions Indian/Native American tribal governments other than federally recognized.

Are minority-serving institutions (MSIs) specifically included as eligible?

Yes. The opportunity explicitly calls out Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).

Can faith-based or community-based organizations apply?

Yes. Faith-based or community-based organizations are explicitly listed among eligible applicant categories.

Can federal agencies apply?

Yes. Eligible federal agencies are explicitly listed among eligible applicant categories.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are explicitly listed among eligible applicant categories.

Can non-U.S. (foreign) organizations apply?

Yes. The eligibility list explicitly includes non-domestic (non-U.S.) entities (foreign organizations).

Can for-profit organizations apply?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.

Is the grant offered as a discretionary or mandatory program?

It is offered as a discretionary grant.

Which federal agency is offering this opportunity?

The opportunity is offered by the National Institutes of Health (NIH).

What is the activity category associated with this opportunity?

The opportunity is described as being in the Education/Health activity category.

What CFDA number is associated with this opportunity?

The opportunity is associated with CFDA 93.279.

What is the closing date listed for this opportunity?

The original closing date listed is October 25, 2022.

When was the posting record created?

The posting record indicates a creation date of February 26, 2021.

How many awards will NIH make under this opportunity?

The expected number of awards is not specified in the provided information.

Is there an award ceiling (maximum funding amount)?

The award ceiling is not specified in the provided information.

How should applicants think about budget planning given the missing award ceiling?

The provided information does not include budget guidance. In situations like this, applicants generally need to consult the full funding announcement text and align with NIH policy defaults for R01 budgeting and any institute-specific expectations referenced in the full announcement.

What should a strong application clearly explain?

A strong application typically makes three points very concrete: (1) the specific delivery limitation that is blocking progress, (2) the new platform/approach that will overcome that limitation, and (3) how the improved delivery will enable mechanistic discovery or therapeutic experimentation relevant to HIV and/or SUD.

Is the scope limited to a specific delivery method?

No specific delivery method is mandated in the provided information. The scope is described as broad, as long as the project is centered on improving delivery of relevant cargoes for HIV and/or SUD research.

Does the opportunity allow projects intended for mechanistic research only?

Yes. The description notes that proposals can be purely preclinical or mechanistic, and it emphasizes that delivery advances should enable better mechanistic insight or improved experimental control in HIV and/or SUD research models.